VA
PACB icon

Vident Advisory’s Pacific Biosciences PACB Stock Holding History

Vident Advisory’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-108,680
Closed -$149K – 1511
2024
Q2 		$149K Buy
108,680
+92,526
+573% +$187K ﹤0.01% 1327
2024
Q1 		$60.6K Sell
16,154
-15,159
-48% -$88.8K ﹤0.01% 1305
2023
Q4 		$307K Buy
31,313
+8,179
+35% +$66.9K 0.01% 992
2023
Q3 		$193K Buy
+23,134
New +$264K 0.01% 1127

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vident Advisory's PACB Position: Q3 2024 in Review

Vident Advisory sold out of Pacific Biosciences (PACB) in Q3 2024, closing a stake of 108,680 shares — an estimated $149K sold.

Vident Advisory first reported a position in PACB in Q3 2023 and held it in 4 quarters. The position peaked at $307K in Q4 2023. 226 funds tracked by Wall St. Rank hold PACB as of Q3 2024.

  • Vident Advisory reported no remaining Pacific Biosciences position as of Q3 2024 after selling out during the quarter.
  • Vident Advisory sold 108,680 Pacific Biosciences shares in Q3 2024, an estimated $149K.
  • Vident Advisory first reported a position in Pacific Biosciences in Q3 2023 and held it in 4 quarters.
  • Vident Advisory's Pacific Biosciences position peaked at $307K in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2024.

Based on Vident Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.